Details of issuance or disposal
Report on the exercise status of the Ninth Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
Number of shares delivered during the month: 765,000 shares (new shares: 765,000; transferred treasury shares: 0)
The lower thin line represents the existing number of shares to which these shares will be added.
Shares delivered during the month: 765,000 / shares issued and outstanding as of 31 March 2026: 58,355,783, representing 1.3%. Exercise ratio subject to the exercise restriction: 1.3%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Report on the exercise status of the Ninth Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 765,000 shares (new shares: 765,000; transferred treasury shares: 0) |
| Intended allottee | EVO FUND (issued on 9 March 2026) |
| Dilution Rate | Shares delivered during the month: 765,000 / shares issued and outstanding as of 31 March 2026: 58,355,783, representing 1.3%. Exercise ratio subject to the exercise restriction: 1.3% |
| Total number of issued shares | As of 31 March 2026: 58,355,783 shares → Not disclosed |
| Exercise price | Subject to an exercise price adjustment clause. Exercise prices during the month: ¥338, ¥325, ¥310, ¥307, ¥303, ¥302, ¥299, ¥300 and ¥303. The lower adjustment limit is Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 570,000; exercised during the month: 7,650; unexercised as of the end of April 2026: 547,950 |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restriction under Article 434 of the Listing Regulations. The exercise ratio subject to the exercise restriction is 1.3%. |
| Most recent equity financing | 9 March 2026: Issuance of the Ninth Series of Stock Acquisition Rights (with exercise price adjustment clause), with EVO FUND as the allottee (570,000 rights issued) |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is a report on the monthly exercise status; no reason for the exercises is stated.